0897 (0897) Fair Value & Analysis

Healthcare · Market cap HK$318M

0 0897 0897 · HK

PriceHK$0.2850

Fair ValueHK$0.0800

Upside-71.9%

Quality51/100

Evidence: High Range HK$0.0600 – HK$0.1000

Fair value as of: Jul 2, 2026

From 19 valuation models · updated today

Share price −13.6% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.2800 – HK$0.4750 · fair‑value band HK$0.0600 – HK$0.1000 · the HK$0.2850 price screens above the HK$0.0800 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0897 (0897) currently trades at HK$0.2850, while our model-based Fair Value estimate is HK$0.0800 — implying the stock looks roughly 71.9% overvalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 0897 generated revenue of HK$721M at a net margin of -1.9%. Revenue declined 6.9% year over year. It earns a return on equity of -1.2%. Net debt stands at HK$146M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$721M

Revenue growth (YoY) -6.9%

Net margin -1.9%

Return on equity -1.2%

Free cash flow HK$75.2M FY2025

Operating margin -6.0%

More key figures

EPS (TTM) HK$-0.0100

EPS growth (YoY) -88.3%

Net debt HK$146M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

0897 reported revenue of HK$683M in FY2026 versus HK$1.4B in FY2022, a compound −16.3%/yr. Reported net income was HK$4.0M in FY2026.

Revenue −16.3%/yr

FY22 HK$1.4B

FY23 HK$1.3B

FY24 HK$784M

FY25 HK$745M

FY26 HK$683M

Net income

FY22 −HK$109M

FY23 −HK$20.5M

FY24 −HK$15.4M

FY25 HK$7.1M

FY26 HK$4.0M

Is 0897 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.08	¥26.59	-44%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$26.19	R$26.01	-1%
Hansoh Pharmaceutical Group 3692	HK$29.30	HK$23.90	-18%
Divi's Laboratories Limited DIVISLAB	₹6,639	₹1,281	-81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0897 (0897) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.0800 versus a price of HK$0.2850 — about −72% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 0897?

Our model-based fair value for 0897 is HK$0.0800 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.2850.

What is the quality score of 0897?

0897 has a Quality Score of 51/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0897 (0897)?

0897 reported trailing-twelve-month revenue of about HK$721M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 0897?

The net profit margin of 0897 is about -1.9%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.